Platelet-activating factor and Escherichia coliO157:H7 infections

Area of Science:

• Microbiology and Immunology
• Pediatric Nephrology

Background:

• Platelet-activating factor (PAF) is a phospholipid inflammatory mediator.
• The role of PAF in Escherichia coli O157:H7-associated hemolytic uremic syndrome (HUS) is not fully understood.
• PAF is synthesized by various cells and degraded by PAF-acetylhydrolase (PAF-AH); a specific mutation (G994T) in PAF-AH is linked to deficient activity.

Purpose of the Study:

• To investigate the association between plasma PAF levels and the PAF-AH (G994T) mutation in children with E. coli O157:H7 infection.
• To determine if these factors predict the risk of developing HUS.

Main Methods:

• Plasma PAF concentrations were measured using extraction, thin-layer chromatography, and scintillation proximity assay.
• PAF-AH (G994T) allele frequency was determined using genetic analysis.
• Study groups included children with uncomplicated infection, those who developed HUS, HUS patients, and healthy controls.

Main Results:

• Plasma PAF levels were significantly higher in children with uncomplicated infection and those who later developed HUS compared to healthy controls.
• PAF levels decreased as HUS developed.
• The PAF-AH (G994T) allele was not detected in any of the study participants.

Conclusions:

• Elevated plasma PAF is present in children infected with E. coli O157:H7, irrespective of HUS development.
• PAF levels appear to diminish as HUS progresses.
• The PAF-AH (G994T) mutation is not a contributing factor to HUS risk in this population.